利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.02 秒)

    METHODS OF TREATING COGNITIVE IMPAIRMENT
    1.
    发明申请
    METHODS OF TREATING COGNITIVE IMPAIRMENT 有权
    治疗认知障碍的方法

    公开(公告)号：US20110311473A1

    公开(公告)日：2011-12-22

    申请号：US13165344

    申请日：2011-06-21

    申请人： HUNTINGTON POTTER ,  Gary W. Arendash ,  Steven Bennett ,  Timothy Boyd

    发明人： HUNTINGTON POTTER ,  Gary W. Arendash ,  Steven Bennett ,  Timothy Boyd

    IPC分类号： A61K38/19 ,  A61P25/00 ,  A61K48/00 ,  A61P25/28 ,  A61K38/18 ,  A61K38/17

    CPC分类号： A61K38/193 ,  A01K67/0275 ,  A01K2207/30 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0356 ,  A61K38/1709 ,  A61K38/1816 ,  A61K48/005 ,  C07K14/535 ,  A61K2300/00

    摘要： The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

    摘要翻译： 本发明涉及用于治疗具有认知障碍的人或动物的材料和方法。 在一个实施方案中，该方法包括施用有效量的一种或多种炎性介质，例如，fms相关的酪氨酸激酶3（Flt3）配体，白细胞介素-6（IL-6），巨噬细胞迁移抑制因子（MIF） ），白介素-1（IL-1），白细胞介素-3（IL-3），促红细胞生成素（EPO），血管内皮生长因子A（VEGF-A），缺氧诱导型转录因子（HIF-1alpha） 因子-1（IGF-1），肿瘤坏死因子（TNF），粒细胞集落刺激因子（G-CSF），粒细胞/巨噬细胞集落刺激因子（GM-CSF），巨噬细胞集落刺激因子（M-CSF） ，干细胞因子（SCF），达比泊汀（ARANESP）和金属蛋白酶，需要治疗的动物或人。

    Prevention and treatment of alzheimer'S disease through electromagnetic field exposure
    5.
    发明授权
    Prevention and treatment of alzheimer'S disease through electromagnetic field exposure 有权
    通过电磁场暴露预防和治疗阿尔茨海默氏病

    公开(公告)号：US09238149B2

    公开(公告)日：2016-01-19

    申请号：US13230415

    申请日：2011-09-12

    申请人： Gary W. Arendash ,  Chuanhai Cao ,  Jun Tan

    发明人： Gary W. Arendash ,  Chuanhai Cao ,  Jun Tan

    IPC分类号： A61N1/00 ,  A61N5/02

    CPC分类号： A61N5/02 ,  A61N2/006 ,  A61N2/02

    摘要： The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period.The predetermined frequency, according to a preferred embodiment, is about 918 MHz with a specific absorption rate (SAR) of about 0.25 W/kg+/−2 dB. The predetermined absorption period of this preferred embodiment is about one hour. The treatment period is long-term, being greater than about 6 months and preferably between about 7 and 9 months.

    摘要翻译： 本发明包括通过将电磁场发射源定位在受试者的近端并将受试者暴露于具有预定频率的电磁场以预定的方式来治疗和预防有需要的受试者中的神经障碍，例如阿尔茨海默氏病， 吸收期。 优选地，每个单独的处理（包括以预定频率暴露预定吸收周期）以预定的时间表（优选地每天）持续预定的处理期。 根据优选实施例，预定频率为约918MHz，比吸收率（SAR）为约0.25W / kg +/- 2dB。 该优选实施方案的预定吸收周期为约1小时。 治疗期是长期的，大于约6个月，优选约7-9个月。

    Method of Treating Cognitive Decline and Synaptic Loss Related to Alzheimer's Disease
    6.
    发明申请
    Method of Treating Cognitive Decline and Synaptic Loss Related to Alzheimer's Disease 审中-公开
    治疗与阿尔茨海默病相关的认知衰退和突触损失的方法

    公开(公告)号：US20090016995A1

    公开(公告)日：2009-01-15

    申请号：US11934940

    申请日：2007-11-05

    申请人： Douglas W. Ethell ,  Gary W. Arendash

    发明人： Douglas W. Ethell ,  Gary W. Arendash

    IPC分类号： A61K35/26 ,  A61P25/28

    CPC分类号： C12N15/8509 ,  A01K67/0271 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0312 ,  A61K35/17 ,  A61K35/26 ,  A61K39/0007 ,  A61K2039/5158 ,  C07K14/4711

    摘要： A method treating a subject with Alzheimer's disease wherein Aβ-reactive immune cells, splenocytes and lymphocytes, are generated in vitro or in vivo, re-stimulated in vitro, and then adoptively transferred into the cognitively-impaired subject. The population of immune cells can be derived from a donor with a natural or adaptive immune response to Aβ, stimulated by exposure to Aβ in vivo. The donor cells are then collected and re-stimulated by subsequent exposure to Aβ in vitro prior to administration to the subject. Alternatively, the population of immune cells can be derived from the subject and then stimulated by exposure to Aβ in vitro.

    摘要翻译： 在体外或体内产生Abeta反应性免疫细胞，脾细胞和淋巴细胞的阿尔茨海默氏病治疗受试者的方法在体外重新刺激，然后过度转移到认知受损受试者中。 免疫细胞群可以从具有对Abeta的天然或适应性免疫应答的供体衍生，通过在体内暴露于Abeta刺激。 然后在施用给受试者之前收集供体细胞并随后再暴露于Abeta再刺激。 或者，免疫细胞群体可以从受试者中获得，然后通过体外暴露于Abeta来刺激。

    MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION
    7.
    发明申请
    MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION 审中-公开
    用于预防或治疗与ABETA PEPTIDE累积相关的神经营养因子的材料和方法

    公开(公告)号：US20110243957A1

    公开(公告)日：2011-10-06

    申请号：US13120633

    申请日：2009-09-24

    申请人： Valentina Echeverria Moran ,  Gary W. Arendash

    发明人： Valentina Echeverria Moran ,  Gary W. Arendash

    IPC分类号： A61K39/395 ,  A61K31/404 ,  A61K31/44 ,  A61K31/166 ,  A61K31/7088 ,  A61K38/17 ,  A61P25/28 ,  C12N5/0793

    CPC分类号： A61K31/404 ,  A61K31/167 ,  A61K31/44 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/11 ,  C12N2310/14

    摘要： The subject invention concerns methods for preventing and/or treating neurodegenerative conditions associated with Abeta peptide accumulation in neural tissue in a human or animal. The subject invention also concerns methods for preventing or treating Alzheimer's disease-like neuropathology in a person or animal having trisomy 21 (Down's syndrome). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of a compound that inhibits function or activity of a Raf protein to a person or animal in need of treatment. In a specific embodiment, the Raf inhibitor is Sorafenib (NEXAVAR). Neurodegenerative conditions contemplated within the scope of the present invention include, for example, Alzheimer's disease and Parkinson's disease. The subject invention also concerns methods for preventing or inhibiting neuronal cell death and/or improving cell viability.

    摘要翻译： 本发明涉及用于预防和/或治疗与人或动物的神经组织中的Aβ肽积累相关的神经变性病症的方法。 本发明还涉及在具有21三体（唐氏综合征）的人或动物中预防或治疗阿尔茨海默病样神经病理学的方法。 在一个实施方案中，本发明的方法包括向需要治疗的人或动物施用治疗有效量的抑制Raf蛋白的功能或活性的化合物。 在具体实施方案中，Raf抑制剂是索拉非尼（NEXAVAR）。 在本发明范围内考虑的神经变性条件包括例如阿尔茨海默氏病和帕金森氏病。 本发明还涉及用于预防或抑制神经元细胞死亡和/或改善细胞活力的方法。

    PREVENTION AND TREATMENT OF BRAIN DISEASES AND DISORDERS RELATED TO ABNORMAL PROTEIN AGGREGATION THROUGH ELECTROMAGNETIC FIELD TREATMENT
    9.
    发明申请
    PREVENTION AND TREATMENT OF BRAIN DISEASES AND DISORDERS RELATED TO ABNORMAL PROTEIN AGGREGATION THROUGH ELECTROMAGNETIC FIELD TREATMENT 审中-公开
    通过电磁场处理与异常蛋白质聚集相关的脑疾病和疾病的预防和治疗

    公开(公告)号：US20160106997A1

    公开(公告)日：2016-04-21

    申请号：US14976986

    申请日：2015-12-21

    申请人： Gary W. Arendash ,  Chuanhai Cao ,  Jun Tan

    发明人： Gary W. Arendash ,  Chuanhai Cao ,  Jun Tan

    IPC分类号： A61N2/00 ,  A61N2/02

    CPC分类号： A61N2/006 ,  A61N2/02 ,  A61N5/02

    摘要： A method of treating and preventing a neurological disorder, such as Alzheimer's disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency (preferably ≈300-3,000 MHz) for a predetermined absorption period (preferably greater than ≈3 days). Each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule for a predetermined treatment period. The EMF can have a specific absorption rate up to about 8 W/kg. The methodology enhances cognition in the subject and/or treats/prevents the underlying neurological disorder or a symptom thereof.

    摘要翻译： 通过将电磁场发射源定位在受试者的近侧并将受试者暴露于具有预定频率的电磁场（优选地≈300-3,000）的方法来治疗和预防有需要的受试者中的神经障碍，例如阿尔茨海默病 MHz），预定吸收周期（优选大于≈3天）。 在预定的治疗期间，以预定的时间表继续进行每个单独的处理（包括以预定的频率暴露预定的吸收期）。 EMF可以具有高达约8W / kg的比吸收率。 该方法增强受试者的认知和/或治疗/预防潜在的神经障碍或其症状。

    PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE THROUGH ELECTROMAGNETIC FIELD EXPOSURE
    10.
    发明申请
    PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE THROUGH ELECTROMAGNETIC FIELD EXPOSURE 有权
    通过电磁场暴露预防和治疗阿尔茨海默病

    公开(公告)号：US20120065456A1

    公开(公告)日：2012-03-15

    申请号：US13230415

    申请日：2011-09-12

    申请人： Gary W. Arendash ,  Chuanhai Cao ,  Jun Tan

    发明人： Gary W. Arendash ,  Chuanhai Cao ,  Jun Tan

    IPC分类号： A61N2/02

    CPC分类号： A61N5/02 ,  A61N2/006 ,  A61N2/02

    摘要： The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period.The predetermined frequency, according to a preferred embodiment, is about 918 MHz with a specific absorption rate (SAR) of about 0.25 W/kg+/−2 dB. The predetermined absorption period of this preferred embodiment is about one hour. The treatment period is long-term, being greater than about 6 months and preferably between about 7 and 9 months.

    摘要翻译： 本发明包括通过将电磁场发射源定位在受试者的近端并将受试者暴露于具有预定频率的电磁场以预定的方式来治疗和预防有需要的受试者中的神经障碍，例如阿尔茨海默氏病， 吸收期。 优选地，每个单独的处理（包括以预定频率暴露预定吸收周期）以预定的时间表（优选地每天）持续预定的处理期。 根据优选实施例，预定频率为约918MHz，比吸收率（SAR）为约0.25W / kg +/- 2dB。 该优选实施方案的预定吸收周期为约1小时。 治疗期是长期的，大于约6个月，优选约7-9个月。